Last updated: 11/07/2018 10:14:29
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Trial description: This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Number of participants with any adverse event (AE) or any serious adverse event (SAE)
Timeframe: From Baseline through Week 52
Number of participants with any hypoglycemic event
Timeframe: From Baseline through Week 52
Secondary outcomes:
Change from Baseline in glycosylated hemoglobin (HbA1c) at Week 52
Timeframe: Baseline and Week 52
Percentage of participants achieving clinically meaningful levels of HbA1c (i.e., the percentage of participants achieving treatment goal of <6.5% and <7.0% at Week 52)
Timeframe: Week 52
Change from Baseline in fasting plasma glucose (FPG) at Week 52
Timeframe: Baseline and Week 52
Change from Baseline in body weight at Week 52
Timeframe: Baseline and Week 52
Time to study withdrawal due to hyperglycemia
Timeframe: Week 52
Interventions:
Enrollment:
374
Primary completion date:
2015-27-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Inaha Okuda, Timothy Wilson, Lin Yue, Hiromu Nakajima, Molly C. Carr, Maho Tsuboi, Antonio Nino. ADA 2016: Albiglutide, a Weekly GLP-1 Agonist, Improved Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Subjects Over 1 Year When Added to Single Oral Antihyperglycemic Medications. Diabetes.2016;65(1):A279.
Medical condition
Diabetes Mellitus
Product
albiglutide
Collaborators
Not applicable
Study date(s)
February 2013 to January 2015
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
No
- Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication
- Body mass index (BMI) 17 to 40 kg/ m2 inclusive
- History of type 1 diabetes mellitus
- Female subject is pregnant, lactating, or <6 weeks postpartum
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication
- Body mass index (BMI) 17 to 40 kg/ m2 inclusive
- Subjects with an HbA1c between 7.0% and 10.0% at Screening
- Creatinine clearance >30 mL/min (calculated using the Cockcroft-Gault formula)
Exclusion criteria:
- History of type 1 diabetes mellitus
- Female subject is pregnant, lactating, or <6 weeks postpartum
- Clinically significant cardiovascular and/or cerebrovascular disease
- Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator
- Serum amylase >=3 ×ULN and/or serum lipase >=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis
- Prior use of a GLP-1R agonist or DPP-IV inhibitor within 6 months before Screening
Trial location(s)
Showing 1 - 6 of 49 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2015-27-01
Actual study completion date
2015-27-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website